### [Chen et al. Page 1575][1] Chen and colleagues analyzed next generation sequencing of 216 advanced thyroid carcinomas identifying prevalent targetable MAPK pathway activating mutations. Secondary mutations in PIK3CA which may confer resistant to single agent targeted therapy were 8x more

中文翻译：

---

本期要点

### [Chen et al。Page 1575] [1] Chen及其同事分析了216个晚期甲状腺癌的下一代测序，确定了普遍可靶向的MAPK途径激活突变。PIK3CA中可能赋予单药靶向治疗耐药性的二次突变多了8倍